Of the 31 analysts tracking the stock, 30 have a ‘buy’ or ‘outperform’ rating while one has a ‘hold’ rating. On aggregate, these analysts expect the stock price to hit ₹1,904.6, which translates into a 20.1% upside potential from the current levels, showed a Bloomberg poll of analysts.
Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge?
Aarti Pharmalabs shares have surged 33% in two days after the company reported a 65.4% year-on-year rise in Q1FY27 profit and 38.7% growth in revenue.